iShares Nasdaq US Biotechnology/£BTEK

1D1W1MYTD1Y5YMAX

About BTEK ETF

The investment objective of the Fund is to seek to provide investors with a total return, taking into account both capital and income returns, which reflects the return of the NASDAQ Biotechnology Index. The Index measures the performance of companies listed on the NASDAQ Stock Market that are classified as either biotechnology companies or pharmaceutical companies, according to their Industry Classification Benchmark (ICB) and that also meet other eligibility criteria as determined by NASDAQ, Inc. (the Index Provider), including minimum market capitalisation and liquidity requirements.
Ticker
£BTEK
Fund name
iShares Nasdaq US Biotechnology
Primary listing
LSE
Fund Manager
BlackRock
Share currency
GBP
Benchmark
NASDAQ Biotechnology Index (Net Total Return)
USD
6
Documents
Key information document
Costs disclosure document

BTEK Metrics

£880M
-

BTEK Fund Highlights

This fund aims to track the Nasdaq Biotechnology index, which covers Nasdaq listed companies primarily engaged in biomedical research to develop new treatments and cures for human disease.
6.29%
Accumulating
0.35%
0.75%
0.03%

BTEK Fund Breakdown

Top holdingsSectorsCountries
Amgen

8.57%

Vertex Pharmaceuticals

8.05%

Gilead Sciences

7.34%

Regeneron

5.02%

Revolution Medicines

2.74%

Alnylam Pharmaceuticals

2.70%

Biogen

2.13%

Illumina

2.05%

Royalty Pharma

1.86%

Other

59.54%

Other funds tracking NASDAQ Biotechnology Index (Net Total Return)

Similar funds
Fund name
iShares Nasdaq US Biotechnology
$BTECAccUSD
$1.2B0.35%
Compare
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.